Colin Levey takes a look at this network meta-analysis of 46 RCTs assessing techniques and drugs for achieving pulpal anaesthesia for the non-surgical endodontic treatment of mandibular molars.
[read the full story...]
This review of the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) as premedication on the success of inferior alveolar nerve block includes 13 RCTs suggesting NSAIDs have a positive impact on success.
[read the full story...]
This randomised controlled trial of a single, preoperative oral dose of prednisolone on post-endodontic pain involved 400 patients demonstrating a significant reduction in pain at 6,12 and 24 hours.
[read the full story...]
16 RCTs involving 1900 patients were included in this review of pre-op analgesia for patients with pulpitis . The findings suggest that premedication with analgesics improves the success rate of local anaesthesia.
[read the full story...]
The review of NSAIDs for endodontic postoperative pain suggests that NSAIDs are effective. A combination of ibuprofen 600 mg and acetaminophen 1000 mg and Ibuprofen 600 mg were both effective. More studies are need to assess teh most effective NSAIDs dosages and does intervals.
[read the full story...]
The aim of this Cochrane review was to assess the effectiveness, safety and acceptability of treatments for oral leukoplakia in preventing oral cancer.
[read the full story...]
This overview of adverse event rates associated with single dose oral analgesics includes data from 39 Cochrane reviews, and provides evidence that adverse events rates are generally similar with active drug and placebo.
[read the full story...]
Helge Hasselmann highlights a recent systematic review of anti-inflammatory drugs for depression, which concludes that NSAIDs, in particular celecoxib, decreases depressive symptoms without increased risk of adverse effects. However, the meta-analysis has a number of draw-backs, which make the study findings far from convincing.
[read the full story...]
There is an increasing body of research that suggests that inflammation plays an important role in the development of schizophrenia. It is therefore logical to consider using anti-inflammatory drugs as a component within the overall treatment approach for people with schizophrenia. This new systematic review and meta-analysis carried out by researchers from the University Medical [read the full story…]
